Memory Disorders Clinical Trials

Stanford Memory Disorders Clinical Trials

Healthy Brain Aging Study

This is a longitudinal study enrolling individuals with Alzheimer’s disease, Mild Cognitive Impairment, Lewy Body Dementia, Parkinson’s disease, Parkinson’s disease with dementia and healthy volunteers. It is funded by the National Institute of Health and is part of the Alzheimer’s Disease Research Center (ADRC). This study will collect data including medical history, family history and medication. There will be questionnaires to be filled out, cognitive testing and MRI of the brain. This study will follow participants over time.
Status: Active recruiting
PI: Victor Henderson, MD
CO-PI: Tony Wyss-Coray, PhD
memoryresearch@stanford.edu
(650) 724-8736

Neurodegeneration and Brain Function in Aging with HIV and Parkinson's Disease

Sponsor: NIH/NINDS
Site PI: Helen Bronte-Stewart, M.D., M.S.
Study Status: Open, enrollment ongoing
Research coordinator: Varsha Prabhakar
varshap@stanford.edu, (650) 721-5295

The Stanford Udall Center

Sponsor: NIH/NINDS Morris K. Udall Center of Excellence for Parkinson's Disease Research
PI: Tom Montine, MD
Study status: Open, Enrollment ongoing
Research coordinator: Christina Wyss-Coray
ADRCstanford@stanford.edu (650) 721-2409

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks for 100 weeks.
Status: Closed to enrollment, study activities continuing
PI: Sharon J. Sha, MD MS
memoryresearch@stanford.edu
(650) 724-8736
NCT02670083

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease (221AD302)

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD.
Status: Active recruiting
PI: Sharon J. Sha, MD MS
memoryresearch@stanford.edu
(650) 724-8736
NCT02484547

Efficacy and Safety Trial of MK-8931 in Participants with Prodromal Alzheimer's Disease

A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease.
Status: Closed to enrollment, study activities continuing
NCT01953601
PI: Sharon J. Sha, MD MS
Research coordinator: Jenn Gaudioso
jenn.gaudioso@stanford.edu (650) 724-4131

Stanford Brain Bank Program

This study seeks a broad range of participants with neurological disorders, including Alzheimer’s disease, Parkinson’s disease, Lewy Body Disease, and other disorders of the brain.  We also seek healthy older adults age 65 and older without a brain disorder to serve as controls.   Participants will be asked to consider brain donation at the time of death.  Autopsy tissues will be used to help our scientists better understand neurodegenerative disorders and other brain diseases, by comparing clinical and autopsy findings and by examining microscopic, biochemical and genetic features.  The pathologist’s brain autopsy report will be provided to family members. 
Status: Active, recruting, limited to current or past Stanford Health Care patients.
PI: Victor Henderson, MD, MS, Co-PI: Edward Plowey, MD, PhD
Research coordinator: Christina Wyss-Coray, RN
cwysscoray@stanfordhealthcare.org, (650) 721 2409

High Resolution Imaging of Hippocampal Mechanisms in Age-Related Memory Decline

This study will enroll healthy older adults without memory complaints to better understand the processes and mechanisms of memory that change as we age.
Status: Active recruiting
PI:  Anthony Wagner, PhD
Research coordinator: Manasi Jayakumar
agingstudy@stanford.edu, (650) 498 0444

Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Closed to enrollment, study analysis continuing
PI: Sharon J. Sha, MD MS (NCT01677572)
Research coordinator: Sia Boumis
siaboumis@stanford.edu, (650) 736-1711

Structural Correlates of Cognitive and Motor Dysfunction in Parkinsonian Disorders

Status: Active closed to enrollment
PI: Kathleen Poston, MD, MS
Research coordinator: Marian Shahid, MSc
mshahid@stanford.edu (650) 723-0060 

Development of Multimodal Imaging Biomarkers for Cognitive Dysfunction in Parkinson's Disease

Sponsor: The Michael J. Fox Foundation for Parkinson’s disease Research
PI: Kathleen Poston, MD, MS
Study status: Enrollment closed, study ongoing
Research coordinator: Marian Shahid, MSc
mshahid@stanford.edu (650) 723-0060 

Functional Networks in Parkinson's Disease - an fMRI Activation and Functional Connectivity Study

Sponsor: NIH/NINDS
PI: Kathleen Poston, MD, MS
Study Status: Enrollment closed, analysis ongoing
Research coordinator: Marian Shahid, MSc
mshahid@stanford.edu (650) 723-0060 

A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson’s Disease

Clinical Trials Protocol #: NCT00400634
Sponsor: Sangamo Biosciences, Inc
Site PI: Kathleen Poston, MD, MS
Study Status: Closed, publication available
Research coordinator: Marian Shahid, MSc
mshahid@stanford.edu (650) 723-0060 

Early Differential Diagnosis of Parkinsonism with Metabolic Imaging and Pattern Analysis

Sponsor: NIH/NINDS and The Michael J. Fox Foundation for Parkinson’s disease Research
Site PI: Kathleen Poston, MD, MS
Study status: Enrollment closed, analysis ongoing
Research coordinator: Marian Shahid, MSc
mshahid@stanford.edu (650) 723-0060 

IDEAS: Imaging Dementia-Evidence for Amyloid Scanning

An observational, open-label, longitudinal cohort study designed to assess the impact of amyloid PET on patient-oriented outcomes in Medicare beneficiaries with mild cognitive impairment (MCI) or dementia of uncertain etiology
Status: Open for Enrollment, 65 years old and older, Medicare beneficiary
PI: Sharon J. Sha, MD MS
memoryresearch@stanford.edu
(650) 724-8736
NCT02420756

PET/MRI of Neurological Disease

Details: The purpose of the study is to identify novel metrics for these imaging markers when they are acquired simultaneously as compared to the current standard of sequential imaging
P.I.: Greg Zaharchuk, MD, PhD
Status: Open for Enrollment
Clinical Research Coordinator: Sia Boumis
siaboumis@stanford.edu,  650-245-7454

Simultaneous Acquisition of PET and MRI for Brain Imaging

Details:  The overall goal of this project is to determine the relationships among the different brain imaging biomarkers
P.I.: Minal Vasanawala, MD
Status: Open for Enrollment
Clinical Research Coordinator: Sia Boumis
siaboumis@stanford.edu, 650-245-7454

Clinical trials contacts

memoryresearch@stanford.edu
(650) 724-8736

Sharon Sha, MD, MS
Clinical Assistant Professor, Neurology & Neurological Sciences
Director, Memory Disorders Clinical Trials
ssha1@stanford.edu
(650) 723-5072